Although the study design (Arrobas Velilla et al., 2021) allowed the identification of patients with severe hypercholesterolemia (3,015) and among them sixty-seven carriers of pathogenic FH variants, we believe the performance of the study leaves room for improvement. The gene discussed is FH; the disease is familial hypercholesterolemia.